CD22 and colitis: Lactobacillus-derived metabolites are already known to potentiate immune-checkpoint blockade; e.g., Lactobacillus plantarum restrains colitis-associated tumorigenesis via arachidonic-acid reprogramming and CD22-mediated BCR tuning 39, 40.